SIGMA TAU FINANZIARIA SPA

Form 4

September 28, 2009

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number: 3235-0287

Estimated average

Check this box if no longer subject to Section 16.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005

Form 4 or Form 5 obligations may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

burden hours per response... 0.5

OMB APPROVAL

1(b).

(Print or Type Responses)

	Address of Reporting AU FINANZIAR	IA SPA Symbo	uer Name and Ticker or Trading l BIOPHARMA INC [DORB]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) VIA SUD	(First) (AFRICA, 20,	(Month	e of Earliest Transaction n/Day/Year) /2009	(Check all applicable) Director X 10% Owner Officer (give title Other (specify below)			
	(Street)		mendment, Date Original Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person			
ROME, Lo	5 00144			_X_ Form filed by More than One Reporting Person			
(City)	(State)	(Zip) Ta	able I - Non-Derivative Securities A	cquired, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 3, 4 and 5) (Instr. 8) (A) or	(A) 5. Amount of Securities Ownership Indirect Beneficially Form: Beneficial Owned Direct (D) Ownership Following or Indirect (Instr. 4) Reported (I) Transaction(s) (Instr. 4) (Instr. 3 and 4)			
Common Stock	09/24/2009		P 3 952 569 A \$	253 45,619,236 I (1) Indirect (1)			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: SIGMA TAU FINANZIARIA SPA - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. 6. Date Exercisable and ionNumber of (Month/Day/Year) Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		e	7. Title and A Underlying S (Instr. 3 and	Securities	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrant (right to buy)	\$ 0.278	09/24/2009		J <u>(2)</u>	1		09/27/2009	09/27/2014(3)	Common Stock	1,976,284

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
SIGMA TAU FINANZIARIA SPA VIA SUDAFRICA, 20 ROME, L6 00144		X					
SIGMA TAU INTERNATIONAL SA 19-21 BLVD. DU PRINCE HENRI L-1724 LUXEMBOURG, N4		X					
Sigma-Tau America S.A. 19-21 BLVD. DU PRINCE HENRI L-1724 LUXEMBOURG, N4		X					
Sigma-Tau Pharmaceuticals, Inc. 9841 WASHINGTONIAN BLVD SUITE 500 GAITHERSBURG, MD 20878		X					
Signatures							
/s/ Maurizio Terenzi, Proxy-holder authorized		09/28/200	9				
**Signature of Reporting Person		Date					

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares directly owned by Sigma-Tau Pharmaceuticals, Inc. (?Pharmaceuticals?). Pharmaceuticals is a direct wholly-owned subsidiary of Sigma-Tau America S.A. (?America?). America is a direct wholly-owned subsidiary of Sigma-Tau International S.A. (?International?).

Reporting Owners 2

Edgar Filing: SIGMA TAU FINANZIARIA SPA - Form 4

International is a direct wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A.

- (2) This warrant was issued by the Issuer to Pharmaceuticals in consideration of Pharmaceuticals? purchase of 3,952,569 shares of common stock on September 24, 2009.
- The expiration date of the warrant may be accelerated at the Issuer?s option if the Issuers?s common stock meets certain price thresholds

 (3) and the common shares underlying the warrant are registered for resale pursuant to an effective registration statement or are freely transferable without volume restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended.

Remarks:

Exhibit List

Exhibit 99 - Joint Filer Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.